FORMULATION AND ANALYTICAL METHOD DEVELOPMENT OF ATORVASTATIN–BERBERINE SOLID DISPERSION TABLETS USING AN ANALYTICAL QUALITY BY DESIGN-ORIENTED APPROACH

Atorvastatin is an effective lipid-lowering agent. However, its poor aqueous solubility may limit dissolution and consequently affect its oral bioavailability. Berberine is a naturally occurring alkaloid with several pharmacological activities; however, its pharmaceutical development is also challenged by limited aqueous solubility and low oral bioavailability. The present study was undertaken to formulate an atorvastatin-berberine solid dispersion using polyvinylpyrrolidone K30 (PVP K30) as a hydrophilic carrier and to develop the resulting solid dispersion into a tablet dosage form. The solid dispersion was prepared using an atorvastatin:berberine:PVP K30 ratio of 1:1:5. The prepared tablets were evaluated for their physical characteristics and dissolution performance. In addition, a UV-visible spectrophotometric analytical procedure was developed using an Analytical Quality by Design oriented approach, with wavelength, solvent and scanning speed investigated as analytical variables. The analytical procedure was further evaluated for linearity, precision, accuracy, specificity and sensitivity. The prepared tablets showed a disintegration time of 15 mins, hardness of 5.1 kg/cm2 and friability of 0.60%. At 45 min, the solid dispersion formulation showed 93.45% drug release, compared with 75.49% for the physical mixture and 98.63% for the marketed formulation. The analytical procedure demonstrated a linear response over the investigated concentration range of 2-12 μg/mL, with satisfactory precision and recovery. Overall, the study demonstrated the potential of PVP K30-based solid dispersion for improving the dissolution performance of the atorvastatin-berberine formulation and provides a systematic approach for analytical method development.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24415728
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FORMULATION AND ANALYTICAL METHOD DEVELOPMENT OF ATORVASTATIN–BERBERINE SOLID DISPERSION TABLETS USING AN ANALYTICAL QUALITY BY DESIGN-ORIENTED APPROACH

Sachin W. Lohe, Anshuman Borkar, Ms. K. N. Dhurvey, Kumudini Dhurve et al.
Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
article

FORMULATION AND ANALYTICAL METHOD DEVELOPMENT OF ATORVASTATIN–BERBERINE SOLID DISPERSION TABLETS USING AN ANALYTICAL QUALITY BY DESIGN-ORIENTED APPROACH

Sachin W. Lohe, Anshuman Borkar, Ms. K. N. Dhurvey, Kumudini Dhurve, Pranjali Raut, Gaurav Badwaik
article en

Abstract

Atorvastatin is an effective lipid-lowering agent. However, its poor aqueous solubility may limit dissolution and consequently affect its oral bioavailability. Berberine is a naturally occurring alkaloid with several pharmacological activities; however, its pharmaceutical development is also challenged by limited aqueous solubility and low oral bioavailability. The present study was undertaken to formulate an atorvastatin-berberine solid dispersion using polyvinylpyrrolidone K30 (PVP K30) as a hydrophilic carrier and to develop the resulting solid dispersion into a tablet dosage form. The solid dispersion was prepared using an atorvastatin:berberine:PVP K30 ratio of 1:1:5. The prepared tablets were evaluated for their physical characteristics and dissolution performance. In addition, a UV-visible spectrophotometric analytical procedure was developed using an Analytical Quality by Design oriented approach, with wavelength, solvent and scanning speed investigated as analytical variables. The analytical procedure was further evaluated for linearity, precision, accuracy, specificity and sensitivity. The prepared tablets showed a disintegration time of 15 mins, hardness of 5.1 kg/cm2 and friability of 0.60%. At 45 min, the solid dispersion formulation showed 93.45% drug release, compared with 75.49% for the physical mixture and 98.63% for the marketed formulation. The analytical procedure demonstrated a linear response over the investigated concentration range of 2-12 μg/mL, with satisfactory precision and recovery. Overall, the study demonstrated the potential of PVP K30-based solid dispersion for improving the dissolution performance of the atorvastatin-berberine formulation and provides a systematic approach for analytical method development.

Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
FORMULATION AND ANALYTICAL METHOD DEVELOPMENT OF ATORVASTATIN–BERBERINE SOLID DISPERSION TABLETS USING AN ANALYTICAL QUALITY BY DESIGN-ORIENTED APPROACH — Sachin W. Lohe, Anshuman Borkar, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS